Loading data for ANRO — first visit, this takes a few seconds.

알림

Alto Neuroscience Inc. (ANRO)

NYSE: ANRO · 실시간 가격 · USD

34.26

+0.13 (0.38%)

종가 기준: Aug 19, 2026, 3:59 PM

34.21

-1.95%

애프터마켓: 7:56 PM

0.38% (1D)

매수호가	34.16
시가총액	1.37B
매출 (ttm)	n/a
순이익 (ttm)	-84.24M
베타	1.09
EPS (ttm)	-2.32
P/E (ttm)	n/a
선행 P/E	-10.62
P/B (ttm)	5.59
P/S (ttm)	n/a
Earnings Date	Nov 11, 2026

매도호가	34.43
거래량	129,759
평균 거래량 (20일)	521,974
시가	35.00
전일 종가	34.13
일중 범위	33.80 - 35.34
52주 범위	3.32 - 35.34
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ANRO 소개

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive d...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 2, 2024

직원 수 68

상장 거래소 NYSE

티커 ANRO

웹사이트 https://www.altoneuroscience.com

전체 기업 정보

재무 실적

2025년 Alto Neuroscience의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -63.24M로, 2.94% 증가했습니다.

재무제표

어닝 서프라이즈

Alto Neuroscience가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.65 예상치 상회 0.12, 및 0.00% 전년 대비 성장.

다음 실적 발표

Alto Neuroscience Inc.의 실적 발표 예정일은 Nov 11, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · Simply Wall St.

Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?

Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0...

3일 전 · Simply Wall St.

Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?

Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with...

3일 전 · Simply Wall St.

Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans

Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last ...

1개월 전 · Insider Monkey

Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list. On June 15, ALTO high...

2개월 전 · Motley Fool

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing

COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office m...

2 페이지 중 1

Alto Neuroscience Inc. (ANRO)